Stratagene Builds on Molecular Dx Alliances with Licensing Deal for Aros Bladder Cancer Tests

Sep 13, 2006

In the latest step in its evolving molecular diagnostics strategy, Stratagene last week obtained exclusive rights from Aros Applied Biotechnology to evaluate and license certain gene groups that may be used as cancer biomarkers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Main menu